Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03460769 · ClinicalTrials.gov registry record
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
A clinical trial of Pancreatic Cancer and Chronic Pancreatitis, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 775
- Enrollment target
- 10
- Study locations
NCT03460769: Recruiting study of Pancreatic Cancer and Chronic Pancreatitis, sponsored by M.D. Anderson Cancer Center.
NCT03460769 is a study of Pancreatic Cancer and Chronic Pancreatitis that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 775 participants, above the 390-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% higher). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03460769, a study of Pancreatic Cancer and Chronic Pancreatitis, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 775 participants
- Enrollment target
- 10
- Study locations
Study Summary
The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Similar to all studies that will be coordinated and managed by the CDMC, no patient enrollment will occur at MDACC. All patient recruitment will occur at external sites that are a part of the CPDPC, which are listed in the appended DETECT protocol. The data management systems, auditing, and monitoring effort are supported by the CDMC.
Primary Outcome
The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer Center will monitor protocol and regulatory compliance at all participating institutions.
Conditions Studied
Interventions
- OTHER Data Management and Monitoring
Study Locations (10)
California
- Cedars-Sinai Medical Center - Los Angeles
- Stanford University - Stanford
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic - Rochester
Texas
- Baylor College of Medicine - Houston
- University of Texas MD Anderson Cancer Center - Houston
Florida
- University of Florida - Gainesville
Indiana
- Indiana University - Carmel
Ohio
- Ohio State University - Columbus
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 775 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2027-06-30 |
What NCT03460769 shows while recruiting
NCT03460769 is an observational study that tracks outcomes without assigning an intervention. The registered 775 participants enrollment target is mid-sized for trials with a published cap, above the 390-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% higher).
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Data Management and Monitoring is the first listed.
NCT03460769 lists 10 locations in 7 states (California, Minnesota, Texas).
Frequently Asked Questions
What is clinical trial NCT03460769 about?
NCT03460769 is a clinical study titled "Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)". The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETEC...
What is the current status of trial NCT03460769?
This trial is currently recruiting. The enrollment target is 775 participants. The study started on 2021-04-01. Estimated completion is 2027-06-30.
What conditions does trial NCT03460769 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Chronic Pancreatitis, Diabetes Mellitus Type 3c.
What interventions are being tested in trial NCT03460769?
The interventions under investigation include: Data Management and Monitoring (OTHER).
Who is sponsoring clinical trial NCT03460769?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03460769 being conducted?
This trial has 10 study locations across California, Florida, Indiana, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03460769's enrollment target sits among peer trials
775 18th of 278 higher than 261 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06145763 · 776 participants · NA
A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial
- NCT05642611 · 777 participants · Phase 3
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
- NCT06841679 · 778 participants · Phase 2
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI